Does Dr. BINCY ABRAHAM have financial conflicts of interest?

Dr. BINCY ABRAHAM (MD) has received a total of $1,080,628 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,080,628 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. BINCY ABRAHAM?

According to CMS Open Payments data, Dr. BINCY ABRAHAM received funding from ABBVIE ($318,414), E.R. SQUIBB & SONS, L.L.C ($155,990), and TAKEDA PHARMACEUTICALS U.S.A ($135,841).

Does Dr. BINCY ABRAHAM receive research grants or speaking fees?

Dr. BINCY ABRAHAM has received $1,080,628 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. BINCY ABRAHAM

MDReal-Time Hydrated

Specialty: Internal Medicine, Gastroenterology

Practice Location: HOUSTON, TX 77030

NPI Number: 1578767166

LIFETIME INDUSTRY VALUE

$1,080,628

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABRAHAM is a verified Internal Medicine, Gastroenterology practitioner based in HOUSTON, TX.

Between 2021 and 2024, Dr. ABRAHAM had an overall industry promotional and research financial footprint of $1,080,628 as recorded in the federal CMS Open Payments database.

$1,080,628 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABRAHAM's primary funding source is ABBVIE, which accounts for $318,414 (representing 29.5% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ABBVIE

Rank 1

$318,414

29.5%

E.R. SQUIBB & SONS, L.L.C

Rank 2

$155,990

14.4%

TAKEDA PHARMACEUTICALS U.S.A

Rank 3

$135,841

12.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.